Myasthenia Gravis Inebilizumab Trial

  • STATUS
    Recruiting
  • End date
    Dec 28, 2024
  • participants needed
    252
  • sponsor
    Viela Bio
Updated on 2 April 2021
Investigator
Jack Ratchford, MD
Primary Contact
Viela Bio Investigative Site (5.5 mi away) Contact
+6 other location
corticosteroids
mycophenolate mofetil
azathioprine
immune globulin
anti-musk antibody

Summary

Randomized, double-blind, placebo-controlled, Phase 3, parallel-group study with optional open-label extension.

Description

This study is a phase 3, randomized, double-blind, placebo-controlled study, to be conducted at approximately 100 study sites. Approximately 252 subjects (172 AChR-Ab+ and 80 MuSK-Ab+) will be enrolled. Patients with MG who are positive for anti-AChR or anti-MuSK antibodies will be enrolled and analyzed separately as 2 populations: (1) AChR-Ab+ and (2) MuSK-Ab+. Patients who do not have anti-AChR or anti-MuSK antibodies will not be enrolled. Patients with MGFA classification II, III, or IV disease, MG-ADL score 6, QMG score 11, and use of a corticosteroid and/or non-steroidal immunosuppressant will be included in the study.

All subjects who complete the randomized controlled period will have the option to enroll in a 1.5-year open-label period.

Details
Condition Myasthenia Gravis, Myasthenia Gravis generalised, Myasthenia Gravis (Chronic Weakness)
Treatment IV placebo, Inebilizumab
Clinical Study IdentifierNCT04524273
SponsorViela Bio
Last Modified on2 April 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Diagnosis of MG with anti-AChR or anti-MuSK antibody
MGFA Clinical Classification Class II, III, or IV
MG-ADL score of 6 or greater at screening and at randomization with > 50% of this score attributed to non-ocular items
QMG score of 11 or greater
Subjects must be on
Corticosteroids only, with no dose increase within 4 weeks prior to randomization, or
One allowed non-steroidal IST, with continuous use for at least 6 months prior to randomization and no dose increase within 4 months prior to randomization, or
Combination of (1) corticosteroids with no dose increase within 4 weeks prior to randomization and (2) one allowed non-steroidal IST with continuous use for at least 6 months prior to randomization and no dose increase within 4 months prior to randomization
Allowed ISTs, alone or in combination with corticosteroids, are azathioprine
mycophenolate mofetil, and mycophenolic acid

Exclusion Criteria

Receipt within the 4 weeks prior to Day 1
Cyclosporine (except eye drops)
Tacrolimus (except topical)
Methotrexate
Current use of
Prednisone > 40 mg/day or > 80 mg over a 2-day period (or equivalent dose of other corticosteroids)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note